摘要
目的利用Meta分析观察间歇性雄激素抑制疗法(IAD)治疗前列腺癌的疗效。方法检索PubMed、EMBASE、Cochrane-Library、万方、重庆维普和中国知网,纳入间歇性对比持续性雄激素抑制疗法(CAD)在前列腺癌治疗作用的随机对照试验(RCT),进行方法学质量评价,并采用RevMan 5.2软件进行统计学分析。结果19篇文献(共17个RCT)纳入研究。间歇性雄激素抑制疗法与持续性雄激素抑制治疗相比,在总生存期、肿瘤进展期、肿瘤特异性生存期方面差异均无统计学意义。在面部潮热、乳房胀痛增生、体力下降、头痛这4方面发病率低,而在转氨酶升高、勃起功能障碍、精神症状方面的发生率均无明显差异。结论间歇性雄激素抑制治疗可以作为治疗前列腺癌的有效方法,但仍需要进一步开展高质量、大样本的随机对照试验予以证实。
Objective To study the effect of intermittent androgen deprivation （lAD） in the treatment of prostate cancer. Methods Using databases ofPubMed, EMBASE, Cochrane-Library, Web of Science databases, Wan Fang database, VIP database and CNKI, we searched all randomized studies related to lAD for the treatment of prostate cancer. The quality of the reports included in this meta-analysis was assessed and the Review Manager 5.2 was used for data analysis. Results Total of 19 reports （17 RCTs） were enrolled in the study. Overall survival （OS）, time to progression （TTP） and prostate cancer-specific deaths were similar for all patients who received IAD or CAD. In adverse events： hot flushes, gynecomastia, fatigue and headache were in lower incidence for patients who received lAD; there were no significant difference in liver enzyme increase,erectile dysfunction and depression between IAD group and CAD group. Conclusion This study suggest that IAD is a reasonable treatment option for patients with prostate cancer who wish to avoid side effect. More RCTs are urgently done to validate this outcome.
出处
《中国男科学杂志》
CAS
CSCD
2016年第2期29-36,共8页
Chinese Journal of Andrology
